OBJECTIVES: Parkinson´s disease is a neurodegenerative disorder with an estimated incidence of 40-50 cases per 100,00 habitants per year. In this paper, We set out to estimate the direct medical costs of Parkinson´s disease. In addition, direct medical costs according to age, gender, socio-economic level, severity and educational attainment were evaluated. METHODS: A partial economic evaluation was performed in order to analyse the direct medical costs related to Parkinson´s disease. The analysis took the perspective of the National Institute of Neurology and Neurosurgery (INNN) for the first semester of 2013, including outpatient clinic visits, medications, medical procedures and laboratory tests, these costs were provided from the INNN´s financial managment. A mexican retrospective study of patients having Parkinson´s disease from the INNN provided information on severity, baseline characteristics and socio-demographic characteristics.  RESULTS: Mean first semester direct medical costs per patient on Parkinson´s disease were US$2 366 in 2013. When analyzing cost distribution, no differences were found in the direct medical costs for the modality groups. In severity and gender, costs hadn´t  statistical significance (p-value>.05). On the other hand, costs by grouped age, grouped socio-economic level and educational attainment were statistically different (p-value<.001). Finally, in the generalized linear model analysis, direct medical costs were only predicted by grouped socio-economic level; age, gender, severity or years of schooling weren´t statistically sgnificance in the model. CONCLUSIONS: The first semester direct medical costs per patient on Parkinson´s disease in this study were US$2 366 in 2013. Total direct medical costs by grouped age and educational attainment were statistically different for patients having Parkinson´s disease. In a multivariate analysis, only socio-economic level predicted a higher direct medical cost.